Use of autoantigen-knockout mice in developing an active disease model for pemphigus

被引:194
作者
Amagai, M
Tsunoda, K
Suzuki, H
Nishifuji, K
Koyasu, S
Nishikawa, T
机构
[1] Keio Univ, Sch Med, Dept Dermatol, Shinjuku Ku, Tokyo 1608582, Japan
[2] Keio Univ, Sch Med, Dept Immunol, Shinjuku Ku, Tokyo 1608582, Japan
关键词
D O I
10.1172/JCI8748
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The development of experimental models of active autoimmune diseases can be difficult due to tolerance of autoantigens, but knockout mice, which fail to acquire tolerance to the defective gene product, provide a useful tool for this purpose. Using knockout mice lacking desmoglein 3 (Dsg3), the target antigen of pemphigus vulgaris (PV), we have generated an active disease model for this autoantibody-mediated disease. Dsg3(-/-) mice, but not Dsg3(+/-) littermates, produced anti-Dsg3 IgG that binds native Dsg3, when immunized with recombinant mouse Dsg3. Splenocytes from the immunized Dsg3(-/-) mice were then adoptively transferred into Rag-2(-/-) immunodeficient mice expressing Dsg3. Anti-Dsg3 IgG was stably produced in the recipient mice for more than 6 months without further boosting. This IgG bound to Dsg3 in vivo and disrupted the cell-cell adhesion of keratinocytes. Consequently, the recipient mice developed erosions in their oral mucous membranes with typical histologic findings of PV. In addition, the recipient mice showed telogen hair loss, as found in Dsg3(-/-) mice. Collectively, the recipient mice developed the phenotype of PV due to the pathogenic anti-Dsg3 IgG. This model will be valuable for developing novel therapeutic strategies. Furthermore, our approach can be applied broadly for the development of various autoimmune disease models.
引用
收藏
页码:625 / 631
页数:7
相关论文
共 27 条
[1]   AUTOANTIBODIES AGAINST A NOVEL EPITHELIAL CADHERIN IN PEMPHIGUS-VULGARIS, A DISEASE OF CELL-ADHESION [J].
AMAGAI, M ;
KLAUSKOVTUN, V ;
STANLEY, JR .
CELL, 1991, 67 (05) :869-877
[2]   ANTIGEN-SPECIFIC IMMUNOADSORPTION OF PATHOGENIC AUTOANTIBODIES IN PEMPHIGUS FOLIACEUS [J].
AMAGAI, M ;
HASHIMOTO, T ;
GREEN, KJ ;
SHIMIZU, N ;
NISHIKAWA, T .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1995, 104 (06) :895-901
[3]   The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile [J].
Amagai, M ;
Tsunoda, K ;
Zillikens, D ;
Nagai, T ;
Nishikawa, T .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 40 (02) :167-170
[4]  
Amagai M, 1999, BRIT J DERMATOL, V140, P351
[5]   AUTOANTIBODIES AGAINST THE AMINO-TERMINAL CADHERIN-LIKE BINDING DOMAIN OF PEMPHIGUS-VULGARIS ANTIGEN ARE PATHOGENIC [J].
AMAGAI, M ;
KARPATI, S ;
PRUSSICK, R ;
KLAUSKOVTUN, V ;
STANLEY, JR .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (03) :919-926
[6]   ABSORPTION OF PATHOGENIC AUTOANTIBODIES BY THE EXTRACELLULAR DOMAIN OF PEMPHIGUS-VULGARIS ANTIGEN (DSG3) PRODUCED BY BACULOVIRUS [J].
AMAGAI, M ;
HASHIMOTO, T ;
SHIMIZU, N ;
NISHIKAWA, T .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (01) :59-67
[7]   Antibodies against desmoglein 3 (Pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice [J].
Amagai, M ;
Nishikawa, T ;
Nousari, HC ;
Anhalt, GJ ;
Hashimoto, T .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (04) :775-782
[8]   Pemphigus vulgaris antigen (Desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients [J].
Amagai, M ;
Koch, PJ ;
Nishikawa, T ;
Stanley, JR .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 106 (02) :351-355
[9]  
Amagai M, 1996, Adv Dermatol, V11, P319
[10]   INDUCTION OF PEMPHIGUS IN NEONATAL MICE BY PASSIVE TRANSFER OF IGG FROM PATIENTS WITH THE DISEASE [J].
ANHALT, GJ ;
LABIB, RS ;
VOORHEES, JJ ;
BEALS, TF ;
DIAZ, LA .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (20) :1189-1196